Inhibikase Therapeutics, INC Form 4 insider transactions

Ra Capital Management, L.P. and 3 others reported changes in beneficial ownership of Inhibikase Therapeutics, Inc. common stock on July 29, 2026.

Dennis N Berman, a Director of Inhibikase Therapeutics, Inc., reported multiple transactions in common stock on July 30, 2026.

Inhibikase Therapeutics, Inc. reports the grant of stock options to Director Dennis N. Berman.

David Canner, a Director at Inhibikase Therapeutics, Inc., acquired 155,000 stock options on June 26, 2026, as detailed in a recent SEC Form 4 filing.

Arvind Kush, a Director at Inhibikase Therapeutics, Inc., acquired 155,000 stock options.

Roberto Bellini, a Director at Inhibikase Therapeutics, Inc., acquired 155,000 stock options.

Vincent Aurentz, a Director at Inhibikase Therapeutics, Inc., acquired 155,000 stock options on June 26, 2026.

Director Amit Munshi of Inhibikase Therapeutics, Inc. acquired 155,000 stock options.

Inhibikase Therapeutics director Vincent Aurentz forfeited 255,299 shares of common stock due to a missed acquisition milestone.

Inhibikase Therapeutics' President and Head of R&D, Christopher Cabell, forfeited 338,282 shares of common stock due to an unachieved acquisition milestone.

Inhibikase Therapeutics director Amit Munshi forfeited 19,089 shares of common stock after a merger-related milestone was not achieved.

Inhibikase Therapeutics CEO Mark T. Iwicki was granted 4,982,706 stock options with an exercise price of $2.01, vesting monthly over three years.

Inhibikase Therapeutics' President and Head of R&D, Christopher Cabell, was granted 900,117 stock options with a $2.01 exercise price, vesting over 36 months.

Inhibikase Therapeutics' Chief Financial Officer, David McIntyre, was granted 986,319 stock options with an exercise price of $2.01, vesting over 36 months.

Sands Capital Life Sciences Pulse Fund II, L.P. acquired over 2 million shares of Inhibikase Therapeutics common stock in a public offering.

Inhibikase Therapeutics director Amit Munshi acquired 57,265 common shares as merger consideration for the CorHepta Pharmaceuticals acquisition.

Inhibikase Therapeutics, Inc. filed an amended Form 4 to correct the exercise price of stock options granted to Christopher Cabell, President & Head of R&D, from an unspecified incorrect value to $2.97 per share.

Inhibikase Therapeutics, Inc. has filed an amended SEC Form 4 to correct the exercise price and expiration date of a stock option award granted to CEO Mark T. Iwicki.

Inhibikase Therapeutics, Inc. Director Vincent Aurentz filed an amended Form 4 to correct the exercise price of a previously reported stock option award.

Inhibikase Therapeutics, Inc. Director Vincent Aurentz was granted 108,176 stock options with an exercise price of $1.95, vesting on the earlier of June 30, 2026, or the day prior to the next annual meeting of stockholders.

Inhibikase Therapeutics Director David Canner was granted 108,176 stock options with an exercise price of $1.95, vesting by June 30, 2026.

Inhibikase Therapeutics, Inc. Director Amit Munshi was granted 108,176 stock options with an exercise price of $1.95, vesting by June 30, 2026, as disclosed in a recent SEC Form 4 filing.

Inhibikase Therapeutics, Inc. Director Arvind Kush was granted 108,176 stock options with an exercise price of $1.95, vesting by June 30, 2026.

Inhibikase Therapeutics, Inc. Director Dennis N. Berman was granted 108,176 stock options with an exercise price of $1.95, vesting by June 30, 2026, or the next annual meeting.

Inhibikase Therapeutics, Inc. Director Roberto Bellini was granted 108,176 stock options with an exercise price of $1.95, vesting on June 30, 2026, or earlier.

David McIntyre, CFO of Inhibikase Therapeutics, Inc., reports the acquisition of stock options.

Christopher Cabell, President & Head of R&D at Inhibikase Therapeutics, received stock options to purchase 1,100,705 shares of common stock.

Vincent Aurentz, a director of Inhibikase Therapeutics, Inc. [IKT], was granted stock options to purchase 134,427 shares of common stock on February 21, 2025.

Mark T. Iwicki, CEO of Inhibikase Therapeutics, was granted stock options to purchase 602,346 shares of common stock.

Mark Iwicki, CEO of Inhibikase Therapeutics, acquires stock options exercisable for millions of shares.